Teva Cites ‘Havoc’ as It Takes Drug Label Spat to Supreme Court (1)

Teva Pharmaceuticals USA Inc. is taking a long-running battle over generic drug labeling to the US Supreme Court, asking the justices to hear a case that could have broader ramifications on the cost of medicine.

The petition, obtained by Bloomberg Law, comes after the US Court of Appeals for the Federal Circuit twice ruled that Teva’s label on a copycat version of GlaxoSmithKline Plc’s heart drug Coreg led doctors to prescribe the generic for an infringing use.

The dispute centers on Teva’s “skinny labeling,” a practice under the Hatch-Waxman Act where a generic company leaves a name-brand drug’s patented ...